The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer
European Journal of Cancer2015Vol. 51(17), pp. 2562–2569
Citations Over TimeTop 10% of 2015 papers
Robert J. van Soest, Annemieke J.M. Nieuweboer, Ellen S. de Morrée, Dana Chiţu, Andries M. Bergman, S.H. Goey, Monique M.E.M. Bos, Nelly van der Meer, Paul Hamberg, Ronald de Wit, Ron H.J. Mathijssen
Related Papers
- → Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies(2014)165 cited
- → Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer(2014)130 cited
- → Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer(2021)10 cited
- → Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug–Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients(2017)19 cited
- → Estudio descriptivo de las recomendaciones anticonceptivas en los ensayos clínicos presentados en España. ¿Es necesario un debate?(2009)1 cited